ULTOMIRIS
ULTOMIRIS is a prescription medicine used to treat adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS)
Complement protein 5 (C5), C5, which is part of the complement system, is an important protein that helps the body destroy foreign or damaged cells.
Normally, complement is under control, Normally, control mechanisms in your body keep C5 and other complement proteins from attacking healthy cells.
What C5 does in atypical-HUS, In atypical-HUS, the control mechanisms fail, and uncontrolled C5 activity can result in complement damaging healthy cells.
Uncontrolled C5 can lead to organ damage Uncontrolled C5 activity causes damage to blood vessels, which leads to something called thrombotic microangiopathy (or simply TMA). TMA involves abnormal clotting, damaged red blood cells, and reduced blood flow.
This TMA damage is the cause of the atypical-HUS signs and symptoms you might feel, and it can lead to problems in the kidneys and other vital organs. In atypical-HUS, the risk of TMA complications is lifelong but may be managed.
Built on the foundation of SOLIRIS (eculizumab), ULTOMIRIS work to remove C5 from the bloodstream, helping to prevent the uncontrolled complement activity that causes damage in atypical-HUS.
Prednisone
Prednisone is used to treat many different inflammatory conditions such as arthritis, lupus, psoriasis, ulcerative colitis, allergic disorders, gland (endocrine) disorders, and conditions that affect the skin, eyes, lungs, stomach, nervous system, or blood cells.
IVIG
Intravenous immune globulin (“IVIG”) is a product made up of antibodies that can be given intravenously (through a vein). IVIG is given into a vein (“intravenously”), in an infusion that takes one hour or more. The amount of IVIG you need for each dose depends on your weight as well as the reason you are getting the IVIG:
Plasmapheresis/Apheresis
Plasmapheresis/Apheresis is a process in which the fluid part of the blood, called plasma, is removed from blood cells by a device known as a cell separator. The separator works either by passing the blood at high speed to separate the cells from the fluid or by passing the blood through a membrane with pores so small that only the fluid part of the blood can pass through.
Eculizumab
Eculizumab is the first treatment to be approved to treat adults with anti-AChR Ab+ gMG in more than 60 years. Soliris works to help manage anti-acetylcholine receptor antibody-positive generalized Myasthenia Gravis (anti-AChR Ab+ gMG) by focusing on a specific part of your immune system.
VYVGART
VYVGART is the first treatment that uses a fragment of an IgG antibody to treat adults with anti-AChR antibody positive gMG. VYVGART is a fragment of an IgG antibod
Rituximab
Rituximab is a genetically engineered antibody that depletes CD20+ B-cells and is Food and Drug Administration- approved for treatment of non-Hodgkin lymphoma, CD20+ CLL, and rheumatoid arthritis. It carries a favorable side effects profile.